InvestorsHub Logo
Followers 17
Posts 936
Boards Moderated 0
Alias Born 04/26/2010

Re: biodoc post# 207526

Tuesday, 12/12/2017 10:18:11 AM

Tuesday, December 12, 2017 10:18:11 AM

Post# of 403079
Thanks, BioDoc, but I am not that smart. "Insights" are not really mine - I compiled into one post what has been said elsewhere.

Also, it was pointed to me "in absences of competition" a big pharma co may have the luxury to wait IPIX demands out and down, but not so much in the presence of one. Correct!

I feel that in order to shore up IPIX finances and to ensure a proper p3 trial size and execution Leo needs to partner Brilacidin. The questions then are:

Is it possible that there are more than 1 (or, yikes, 0) serious suitor?
Who might they be?

My thoughts about prospective candidates, if there are any:
Companies having a presence or potential presence (pipeline) in head and neck cancer?
Companies with concerns over declining income from their current product line?
Companies still willing to pay present (or near present) proof of concept rate for Brilacidin?

Explanation for the last point: Some companies, like Novartis, are saying that they see the current acquiring costs of proof of concept stage drugs as too high and plan to go after earlier stage, even preclinical, drug candidates: higher risk, lower cost.

Pfizer with its improving but still not very productive in-house research is perennial contestant on everything. Others?

Old geezer going off topic tangent:
It was said (with unbecoming glee, I admit) about Pfizer research when their fall from grace already had begun that they thought too much alike and somehow managed to be snobby about it. That's an ailment with no fast cure.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News